The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Current and future treatment approaches for secondary fibrosis
In this video, Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses current and future treatment approaches to secondary fibrosis. Dr Mesa first highlights various agents used in the treatment of secondary myelofibrosis (MF), including pelabresib, navitoclax, and anti-fibrosing agents. Dr Mesa then discusses the role of interleukins in the process of developing MF, and how to improve treatment options for patients in the future. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
